Navigation Links
Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Date:9/6/2007

Bukwang Pharmaceuticals under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a Phase 1 clinical trial through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About R7128

R7128 is being developed for the treatment of chronic hepatitis C. R7128 is a prodrug of PSI-6130, which demonstrated potency in preclinical studies. PSI-6130 is a pyrimidine nucleoside analog inhibitor of HCV RNA polymerase, an enzyme that is necessary for hepatitis C viral replication. Results from an oral single ascending dose study of PSI-6130 in 24 healthy male volunteers showed that PSI-6130 was generally well tolerated with no serious adverse events in doses up to 3000 mg.

R7128 Phase 1 Study Overview

The Phase 1 clinical trial is a multiple center, observer-blinded, randomized and placebo-controlled study to investigate the pharmacokinetics, pharmacodynamics, safety, tolerability and food effect of R7128 in healthy volunteers and in patients chronically infected with HCV genotype 1. This Phase 1 study is comprised of two parts:

-- Part 1 is a single ascending dose study of R7128 conducted in 46

healthy volunteers. The primary objective of Part 1 is to assess the

safety, tolerability and pharmacokinetics of R7128 following single

ascending doses under fasting conditions. The secondary objective of

Part 1 is to explore the effect of food on the pharmacokinetics of

R7128. Preliminary data from the single ascending dose portion of the

study indicate:

-- All doses of R7128 studied were generally safe and well-tolerated.

-- All patients completed the study, and none experienced

gastrointestinal adverse events or serious adverse events during

the study.

-- No hematological or la
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Advantages of Roche Applied Science amplification products
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
5. Prodesse enters patent agreement with Roche
6. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
7. Wisconsin firms to present at Cleantech venture capital event
8. New Sonic Foundry search engine finds words, phrases in video presentations
9. Lone Wisconsin firm to present at InvestMidwest
10. Sonic Foundry creates search engine for 7,000 expert video presentations
11. InvestMidWest calls for business presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... With the accelerated aging of ... expenditure as well as the improved medical care ... reagent industry has been developing quickly, especially in ... Chinese in vitro diagnostics market size reached RMB22.98 ... vitro diagnostic reagents. , Read complete report ...
(Date:7/30/2014)... Yuma Regional Cancer Center Officially ... brings comprehensive cancer care to Yuma, Arizona. , ... Center has officially opened. A Mayo Clinic Care ... such as open, semi-private and private infusion rooms, ... Resource Center, hematology, rehabilitation center, a pain management ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... novel diagnostics to personalize and advance the treatment and ... Gregory T. Lucier as chairman of Epic,s board ... of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s ... its circulating rare cell analysis platform with special focus ...
(Date:7/30/2014)... 30, 2014 Connecticut Center for Advanced ... in East Hartford, Conn., was awarded a Rural Business ... a project that will determine the feasibility of implementing ... Connecticut. USDA Rural Development provided $53,000 for CCAT under ... second phase of the feasibility study in fiscal year ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... SEATTLE, July 9 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... Providers Act of 2008, as passed by the U.S. ... Senate on July 9, 2008, would,continue the 2007 reimbursement ... a start date of July,1, 2008. In December, Congress ...
... Compensatory Award Will Now Proceed -, MADISON, N.J., July ... motion for judgment as a matter of law on the,punitive ... v.,Wyeth, in the U.S. District Court, Eastern District of Arkansas, ... damages award of,$19,360,000 rendered by the Little Rock jury last ...
... ARBOR, Mich., July 9 Terumo Cardiovascular Systems,(Terumo ... infringement complaint in,Germany against two affiliates of Maquet ... Vertriebs und Service Deutschland GmbH. The complaint,alleges that ... Vessel Harvesting Systems, infringe a patent for which ...
Cached Biology Technology:Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 2Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 3Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months 4Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 2Wyeth's Motion to Overturn Punitive Damages Award Granted by Arkansas Court 3Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates 2
(Date:7/30/2014)... HIV infection could be as simple as inserting a ... University of Washington bioengineers have discovered a potentially faster ... from contracting HIV. Their method spins the drug into ... moisture, releasing higher doses of the drug than possible ... , "This could offer women a potentially more effective, ...
(Date:7/30/2014)... humans figured out how to create colors, nature had ... wings of many different hues, for example. Now scientists ... environmentally friendly way to make colored plastics. Their paper ... of materials rather than dyes, to produce color ... , N. Asger Mortensen, Anders Kristensen and colleagues point ...
(Date:7/30/2014)... been awarded the Scientific Committee on Antarctic Research,s ... , SCAR, an inter-disciplinary international science body, initiates, ... in the Antarctic region, and on the role ... The organisation also provides scientific advice about Antarctica ... the region. , The medal is open internationally ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... The Scripps Research Institute has been awarded a $500,000 ... pair of genetic mutations that could lead to a new ... and fatal neurodegenerative disorder. Philip LoGrasso, PhD, a professor ... Scripps Florida, is the principal investigator for the project. ...
... DeKalb, Ill. -- It,s safe to say Northern Illinois ... cats. She keeps two tabbies at her Hampshire, Ill. home. ... anything but cute and cuddly -- the prehistoric saber-tooths. ... of Kansas and fossil hunter John Babiarz -- are editors ...
... warming and its impact on our environment have left ... humans produce. Now, Tel Aviv University researchers are doing ... growing forests in the most unlikely place deep ... such as a local plant species, recycled sewage water ...
Cached Biology News:Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 2Scripps Research scientist awarded $500,000 grant to study Parkinson's disease 3NIU biologist Virginia Naples is helping put new face on ferocious saber-tooth cats 2NIU biologist Virginia Naples is helping put new face on ferocious saber-tooth cats 3Growing something out of nothing 2
RECOMBINANT EQUINE TNF ALPHA Product Type: Recombinant Protein...
... contains 5 ml of DETACHaBEAD 19 ... Dynabeads CD19 (Pan B). B ... B) and released with DETACHaBEAD CD19 ... are suitable for applications such as ...
... Buffers are supplied as 10X concentrated solutions. REact ... each of the REact buffers and one 250 ... of four 1 ml vials of REact 1 ... Buffer four 1 ml vials of REact 3 ...
... The Vybrant Apoptosis Assay Kit #4 ... changes that occur in the permeability of ... of both YO-PRO-1 and propidium iodide nucleic ... the plasma membranes of apoptotic cells and ...
Biology Products: